Risk Minimisation Materials

Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Patient Alert Card

Patient Alert Card

Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Patient Information Brochure

Patient Information Brochure - Important safety information to minimise the risk of immune-related side effects

Valproate - Healthcare Professional Booklet

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

For Healthcare Professionals

Valproate Annual Risk Acknowledgement Form

Patient Risk Acknowledgement Form. Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Valproate- Healthcare professionals (HCPs) Educational material Pregnancy prevention programme

Guide about use of valproate in pregnancy. Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

For Healthcare Professionals

Valproate-Patient guide-Educational material-Pregnancy prevention programme

Guide on use of valproate during pregnancy. Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Valproate-Poster-Dispensary-Pregnancy Prevention Programme

Poster - Dispensary. Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

For Healthcare Professionals

Benepali Healthcare Professional Training Guide

Brief Training on additional risk minimization measures for HCPs

For Healthcare Professionals

Benepali Patient Alert Card

PAC contains important information that patients need to be aware of.

Benepali Quick Reference Guide for pre-filled pen

This guide is designed to offer quick reference on how to inject safely and effectively.

Benepali Quick Reference Guide for pre-filled syringe

This guide offers quick reference on how to inject safely and effectively.

Beovu (Brolucizumab) - Patient Guide to Therapy - for patients

This guide contains important information about Beovu (Brolucizumab) why its been prescribed, side effects and their potential risks.

Bivaluridin Accord dosing and administration instruction for medically managed ACS patients with urgent or early intervention

This document will serve as a guide to HCP on dosing and administration of Bivaluridin Accord for medically managed ACS patients with urgent or early intervention.

For Healthcare Professionals

Bivaluridin Accord dosing and administration instruction for PCI and Primary PCI

This document will provide instruction for dosing and administration of Bivaluridin Accord following PCI and primary PCI

For Healthcare Professionals

Bivaluridin Education Material for medically managed ACS patients

Bivaluridin Education Material for medically managed ACS patients: Treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. Bivalirudin should be administered with acetylsalicylic acid and clopidogrel.

For Healthcare Professionals

Bivaluridin Education Material for PCI and Primary PCI

After reconstitution 1ml contains 50mg bivalirudin. After dilution 1ml contains 5mg bivalirudin. Indications: Bivalirudin is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Bivalirudin is also indicated for the treatment of adult patients with unstable angina/ non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. Bivalirudin should be administered with acetylsalicylic acid and clopidogrel.

For Healthcare Professionals

BLINCYTO Guide for Nurses

This educational brochure contains important information regarding the administration of BLINCYTO and the risks of medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks and therefore it is advised to be read carefully before administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Guide for Patients and Caregivers

This educational brochure contains important information you should know before receiving BLINCYTO. This educational material is essential to ensure the safe and effective use of the drug and appropriate management of the important selected risks. Please read it carefully before taking the medicinal product. To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441

BLINCYTO Guide for Pharmacists

This educational brochure contains important information regarding the reconstitution and preparation procedures for blinatumomab. To ensure the safe and effective use of the medicinal product and appropriate management of the important selected risks, please carefully read this material before reconstituting and preparing of the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Guide for Physicians

This educational brochure contains important information regarding the administration of BLINCYTO and the risks of medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks and therefore it is advised to be read carefully before prescribing and administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Patient Alert Card

This BLINCYTO patient alert card contains a warning message for HCPs that the patient is using BLINCYTO, includes contact details of the BLINCYTO prescriber and treatment start date, and information on the importance of reporting ADRs. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441

Dosing Slide Rule - Bortezomib 2.5mg/ml Solution for Injection (3.5mg total content)

Tool for calculating body surface area inc. reconstiution/method of administration instructions for Bortezomib 2.5mg/ml Solution for Injection (3.5mg total content).

For Healthcare Professionals

Reconstitution Dosing and Administration Book - Bortezomib 2.5mg/ml Solution for Injection (3.5mg total content)

Guide for reconstitution, dosing and administration of Bortezomib 2.5mg/ml Solution for Injection (3.5mg total content) for SC and IV use.

For Healthcare Professionals

Reconstitution Poster - Bortezomib 2.5mg/ml Solution for Injection (3.5mg total content)

Visual reminder of the correct reconstitution, dosing and administration guidance of Bortezomib 2.5mg/ml Solution for Injection (3.5mg total content) for SC and IV use.

For Healthcare Professionals

Transplant Induction Regimens Graph

Graph indicating the correct dosing and duration of treatment cycles prior to transplant for Bortezomib when co-administered with either Dexamethasone or Dexamethasone/Thalidomide.

For Healthcare Professionals

Dosing Slide Rule - Bortezomib Dr. Reddy's 3.5 mg Powder For Solution For Injection

Tool for calculating body surface area inc. reconstiution/method of administration instructions for Bortezomib 3.5 mg Powder For Solution For Injection

For Healthcare Professionals

Reconstitution Dosing and Administration book Bortezomib 3.5 mg vial

Guide for reconstitution, dosing and administration of Bortezomib 3.5 mg Powder For Solution For Injection

For Healthcare Professionals

Reconstitution Poster Bortezomib 3.5 mg vial

Visual reminder of the correct reconstitution, dosing and administration guidance of Bortezomib 3.5 mg Powder For Solution For Injection

For Healthcare Professionals

Transplant Induction Regimens Graph Bortezomib 3.5 mg Vial

Graph indicating the correct dosing and duration of treatment cycles prior to transplant for Bortezomib when co-administered with either Dexamethasone or Dexamethasone/Thalidomide

For Healthcare Professionals

Bosentan 62.5 mg and 125 mg film-coated tablets Prescribers guide

This Prescriber’s Guide provides a summary of the most important safety information you should know about bosentan and the following important risks associated with bosentan treatment and how to minimise them

For Healthcare Professionals

Patient card - Bosentan 62.5mg and 125mg film‐coated Tablets

Important Safety Alerts for Patients taking Bosentan Tablets (bosentan)

For Healthcare Professionals

Bosentan Accord - Important Safety Information for Prescribers

This guide includes important safety information which must be considered before a patient is prescribed Bosentan Accord.

For Healthcare Professionals

Bosentan Patient Alert Card

Important Safety Alerts for Patients taking Bosentan Accord (bosentan)

Bosentan Dr. Reddy's 62.5 mg & 125 mg Film-coated Tablets Patient leaflet Important Safety Information

Important Safety Information for the Patient

Bosentan Dr. Reddy's Film-coated Tablets Prescribers Kit

Information for Prescribers

For Healthcare Professionals

Important Safety Alerts for Patients Taking Dr. Reddy's Bosentan 62.5 mg & 125 mg Film-coated Tablets

Patient Alert Card

Bosentan- HCP Presciber Guide

For hard copies please contact our medical information department on 0800 090 2408 or email [email protected] .

For Healthcare Professionals

Bosentan- Patient Alert Guide

This card contains important information about bosentan. Please read this card carefully before starting your treatment with bosentan. For hard copies please contact our medical information department on 0800 090 2408 or email [email protected]

Bosentan Milpharm - Guideline for patients

This guide includes important safety information which must be considered by patients before taking Bosentan Milpharm.

Bosentan Milpharm - Guideline for prescriber

This guide includes important safety information which must be considered before a patient is prescribed Bosentan Milpharm.

For Healthcare Professionals

Bosentan Milpharm - Patient Alert Card

Important Safety Alerts for Patients taking Bosentan Milpharm

Bosentan Mylan - Important Safety Information for Prescribers

This guide includes important safety information which must be considered before a patient is prescribed Bosentan Mylan.

For Healthcare Professionals

Bosentan Patient Alert Card

Important Safety Alerts for Patients taking Bosentan Mylan (bosentan)

Risk Minimisation Information on Potential Risk of Medication Errors - Guide for HCPs

This educational guide is provided to highlight and minimise the potential risk of prescribing and administration errors (medication errors) due to the differences between Braltus (tiotropium bromide) and the originator product Spiriva® HandiHaler® (tiotropium bromide) with respect to the pre-metered dose.

For Healthcare Professionals

Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets Educational material for health care professionals

Educational material for health care professionals Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets For hard copies please contact our medical information department at 0800 090 2408 or email [email protected]

For Healthcare Professionals

Appropriate use of Brinavess - Healthcare Professional Card

Appropriate use of Brinavess - Healthcare Professional Card Brinavess 20 mg/ml concentrate for solution for infusion (vernakalant hydrochloride)

For Healthcare Professionals

Bronchitol Healthcare Professional Leaflet

Bronchitol Healthcare Professional Leaflet

For Healthcare Professionals